J&J seeks authorization for COVID-19 vaccine booster
Johnson & Johnson today announced its request that the Food and Drug Administration amend the current emergency use authorization for the J&J COVID-19 vaccine to include a booster dose. J&J’s submission includes phase 3 U.S. clinical trial data that affirms the booster’s effectiveness; when administered 56 days following a primary dose, J&J said, a booster provided 94% protection against symptomatic (moderate to severe/critical) COVID-19 and 100% protection against severe/critical COVID-19, at least 14 days after booster administration. The submission also includes phase 1/2a data on boosters’ effectiveness at the six-month juncture. The FDA later this month will meet to consider booster for J&J and Moderna.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…